PerpEquities

Laporan laba rugi Arrowhead Pharmaceuticals, Inc. (ARWR)

NASDAQ · Healthcare · Biotechnology · Karyawan: 711 · CEO: Christopher R. Anzalone

Harga
$59,90 -0,98%
Kapitalisasi pasar
$8,46 M
Nilai perusahaan
$9,27 M
Laporan terakhir
Q3 '26 diajukan 2026-08-04
Laporan berikutnya
2026-11-24 Estimasi EPS: -$1,52

Arrowhead Pharmaceuticals, Inc. (ARWR) untuk Q3 '26: pendapatan $75,3 jt (+171,0% yoy), laba operasional -$170 jt (-226,0% dari pendapatan), laba bersih -$194 jt. Dalam empat kuartal terakhir pendapatan mencapai $669 jt.

Laporan laba rugi

Laporan laba rugiTrenQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pendapatan$16,1 jt$3,55 jt$0$0$0$2,5 jt$543 jt$27,8 jt$256 jt$264 jt$73,7 jt$75,3 jt
Beban pokok pendapatan$3,86 jt$4,26 jt$4,53 jt$4,78 jt$5,03 jt$0$0$0$0$0$0$0
Laba kotor$12,2 jt-$712 rb-$4,53 jt-$4,78 jt-$5,03 jt$2,5 jt$543 jt$27,8 jt$256 jt$264 jt$73,7 jt$75,3 jt
Riset & pengembangan$96,4 jt$113 jt$97 jt$148 jt$131 jt$137 jt$133 jt$162 jt$175 jt$177 jt$173 jt$198 jt
Umum & administrasi$24,2 jt$23,2 jt$24,6 jt$23,2 jt$25,8 jt$26,4 jt$27,9 jt$30,4 jt$37,2 jt$45,5 jt$41,2 jt$0
Beban operasional lainnya$0$0$0$0$0$509 rb$511 rb$505 rb$503 rb$504 rb$500 rb$0
Beban operasional$121 jt$136 jt$122 jt$171 jt$157 jt$164 jt$162 jt$193 jt$212 jt$223 jt$215 jt$245 jt
Laba operasional-$108 jt-$137 jt-$126 jt-$176 jt-$162 jt-$161 jt$381 jt-$166 jt$44,1 jt$40,8 jt-$141 jt-$170 jt
Pendapatan bunga$3,89 jt$2,8 jt$6,25 jt$6,5 jt$7,17 jt$7,6 jt$9,62 jt$11 jt$9,05 jt$9,69 jt$16,9 jt$16,9 jt
Beban bunga$5,26 jt$5,37 jt$7,24 jt$5,09 jt$14,6 jt$21,6 jt$21,6 jt$24,4 jt$21,7 jt$22,5 jt$23,8 jt$24,6 jt
Pendapatan non-operasional lainnya (keuntungan investasi, kurs ...)-$4,6 jt-$3,22 jt-$6,44 jt-$7,26 jt-$4,05 jt-$7,94 jt-$10,1 jt-$10,8 jt-$13,7 jt-$9,97 jt-$27,5 jt-$15,8 jt
Total pendapatan non-operasional-$660 rb-$2,14 jt-$805 rb$2,16 jt-$10,6 jt-$13,7 jt-$11,6 jt-$13,5 jt-$7,99 jt-$12,5 jt$3,7 jt-$8,81 jt
Laba sebelum pajak-$109 jt-$139 jt-$127 jt-$174 jt-$173 jt-$175 jt$370 jt-$179 jt$36,1 jt$28,3 jt-$138 jt-$179 jt
Pajak penghasilan$2,03 jt-$3,31 jt$0$0$546 rb$103 rb$1,75 jt-$437 rb$20 jt$29 rb$7 rb$11 rb
Laba bersih-$110 jt-$133 jt-$125 jt-$171 jt-$171 jt-$173 jt$370 jt-$175 jt-$23,8 jt$30,8 jt-$133 jt-$194 jt
EPS (dasar)-$1,02-$1,24-$1,02-$1,38-$1,40-$1,39$2,78-$1,26-$0,17$0,22-$0,93-$1,36
EPS (dilusian)-$1,02-$1,24-$1,02-$1,38-$1,40-$1,39$2,75-$1,26-$0,17$0,22-$0,93-$1,36
Saham (dasar, rata-rata tertimbang)107 jt107 jt123 jt124 jt122 jt125 jt133 jt139 jt136 jt140 jt142 jt143 jt
Saham (dilusian, rata-rata tertimbang)107 jt107 jt123 jt124 jt122 jt125 jt134 jt139 jt136 jt141 jt142 jt143 jt
Depresiasi & amortisasi$3,86 jt$4,26 jt$4,53 jt$4,78 jt$5,03 jt$5,24 jt$6,08 jt$6,22 jt$6,39 jt$6,39 jt$6,37 jt$6,66 jt
EBITDA-$99,9 jt-$129 jt-$115 jt-$164 jt-$153 jt-$148 jt$397 jt-$148 jt$64,2 jt$57,2 jt-$107 jt-$148 jt

Distandardisasi dari laporan perusahaan; arus keluar dan biaya mempertahankan tanda yang dilaporkan penyedia. Arahkan kursor ke periode untuk melihat tanggal berakhirnya. Jumlah dalam USD.

Pendapatan, laba operasional, dan pertumbuhan

kuartalan

Margin

kuartalan

Biaya sebagai % pendapatan

kuartalan

Laporan lainnya

Sumber

Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-Q 2025-12-31, 10-K 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-Q 2024-12-31, 10-K 2024-09-30, 10-Q 2024-06-30

Data per 2026-11-02